Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Price:
24.51 USD
2.51%
Market Closed
Updated:
Jun 11, 2024
Arrowhead Pharmaceuticals Inc
Accounts Payable
|
Arrowhead Pharmaceuticals Inc
Accounts Payable Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
|
Accounts Payable
$8.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
16%
|
CAGR 10-Years
13%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$31.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
$622m
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$1.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$351.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
34%
|
CAGR 10-Years
22%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$671.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
23%
|
CAGR 10-Years
35%
|
See Also
What is Arrowhead Pharmaceuticals Inc's Accounts Payable?
Accounts Payable
8.5m
USD
8.5m
USD
Based on the financial report for Mar 31, 2024, Arrowhead Pharmaceuticals Inc's Accounts Payable amounts to 8.5m USD.
What is Arrowhead Pharmaceuticals Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
13%
13%
Over the last year, the Accounts Payable growth was -11%. The average annual Accounts Payable growth rates for Arrowhead Pharmaceuticals Inc have been 17% over the past three years , 16% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet
